| Nov 7 |
Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates
|
| Nov 7 |
Myriad: Q3 Earnings Snapshot
|
| Nov 7 |
Myriad Genetics Non-GAAP EPS of $0.06 beats by $0.04, revenue of $213.3M beats by $2.51M
|
| Nov 7 |
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
|
| Nov 6 |
Myriad Genetics Q3 2024 Earnings Preview
|
| Nov 6 |
BIIB vs. MYGN: Which Stock Is the Better Value Option?
|
| Nov 4 |
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
|
| Nov 2 |
Myriad weakness due to UnitedHealth coverage update, says Stephens
|
| Nov 1 |
Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage
|
| Oct 30 |
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
|
